CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas

Launched by IMMUNE CELL, INC. · Dec 19, 2017

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called ICAR30, which is designed to target and kill cancer cells that express a protein called CD30. The trial focuses on patients with Hodgkin lymphoma and anaplastic large cell lymphoma, both of which are types of cancers that can be difficult to treat when they come back or do not respond to other therapies. Participants in this study will receive infusions of their own modified immune cells, known as CAR-T cells, which are specially engineered to seek out and attack cancer cells. The researchers will monitor how safe this treatment is and how well it works over time.

To be eligible for this trial, patients should have Hodgkin lymphoma, anaplastic large cell lymphoma, or other cancers that express CD30, and they should be in a condition that allows them to receive treatment. Key criteria include being generally healthy enough to tolerate the therapy and having a life expectancy of at least 12 weeks. Participants can expect to receive several doses of the treatment and will be closely watched for any side effects and the effectiveness of the therapy. This trial is currently recruiting patients of all genders, aged 13 to 90 years.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Hodgkin's lymphoma, anaplastic large cell lymphoma and other CD30 positive malignancies, relapsed or refractory:
• • Karnofsky or Lansky score \>50;
• • Expected survival\>12 weeks;
• • Hgb \> 8.0;
• • FEV1, FVC and DLCO ≥50% of expected corrected for hemoglobin;
• • LVEF≥50%;
• • Creatinine\<2.5mg/dl;
• • Bilirubin\<2.5mg/dl;
• • ALT (alanine aminotransferase)/AST (aspartate aminotransferase)\<3 fold normal;
• • Patients must sign an informed consent.
• Exclusion Criteria:
• • Pregnant or lactating;
• • Uncontrolled active infection including hepatitis B or C;
• • HIV positive;
• • Active clinically significant CNS dysfunction;
• • Current use of systemic steroids;
• • Heterogenous lymphocyte treatments within recent 6 months;